A child with severe juvenile dermatomyositis treated with ruxolitinib

Brain. 2018 Nov 1;141(11):e80. doi: 10.1093/brain/awy255.

Florence A Aeschlimann¹, Marie-Louise Frémond^{1

2

3}, Darragh Duffy^{4

5

6}, Gillian I Rice⁷, Jean-Luc Charuel⁸, Vincent Bondet^{4

5

6}, Elsa Saire¹, Bénédicte Neven^{1

2}, Christine Bodemer^{2

9}, Laurent Balu¹⁰, Cyril Gitiaux^{11

12}, Yanick J Crow^{2

3

13}, Brigitte Bader-Meunier^{1

2

14}

¹ Department of Paediatric Immunology-Haematology and Rheumatology, Necker University Hospital - AP-HP, Paris, France.
² Paris Descartes University, Sorbonne Paris Cité, Imagine Institute, Paris, France.
³ Laboratory of Neurogenetics and Neuroinflammation, INSERM UMR, Paris, France.
⁴ Immunobiology of Dendritic Cells, Institut Pasteur, Paris, France.
⁵ Centre for Translational Research, Institut Pasteur, Paris, France.
⁶ INSERM U1223, Paris, France.
⁷ Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.
⁸ Laboratory of Immunology, La Pitié Hospital - AP-HP, Paris, France.
⁹ Department of Dermatology and Paediatric Dermatology, Necker University Hospital - AP-HP, Paris, France.
¹⁰ Department of Paediatrics, Centre Hospitalier Universitaire, La Réunion.
¹¹ Department of Paediatric Neurophysiology, Necker University Hospital - AP-HP, Paris, France.
¹² Pathophysiological investigations and innovative therapies in neuromuscular disease IMRB U955, Faculté de médecine, Créteil, France.
¹³ Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK.
¹⁴ Laboratory of Immunogenetics of paediatric autoimmune diseases, INSERM UMR, Paris, France.

No abstract available

Publication types